A decade of cell death studies: Breathing new life into necroptosis

Imran Khan, Abdelrahman Yousif, Mikhail Chesnokov, Linda Hong, IIana I. Chefetz

Research output: Contribution to journalArticle

65 Scopus citations


Programmed cell death (PCD) has been a major area of constantly growing interest over the last three decades. Originally, apoptosis was considered the only mechanistic pathway for PCD, but recently several different pathways (i.e., necroptosis, pyroptosis, ferroptosis) have emerged as important in both normal and pathological conditions. This review focuses on programmed cell necrosis (i.e., necroptosis) as a promising research direction that will help us in understanding the molecular and cellular processes behind different pathological conditions, such as chronic inflammation, neurodegeneration, and cardiovascular diseases. In addition, we discuss natural and chemical compounds and novel targeted therapies triggering necroptosis to induce cell death in cancer cells to overcome chemoresistance.

Original languageEnglish (US)
Article number107717
JournalPharmacology and Therapeutics
StatePublished - Apr 2021

Bibliographical note

Funding Information:
This work was supported in part by the Michigan Ovarian Cancer Alliance (MIOCA) , the Liz Tilberis early career OCRA award, the Marsha Rivkin Ovarian Center pilot award , the Elsa U. Pardee foundation , and the WeRoc research grant from Foundation for Women's Cancer (to I.C.)

Publisher Copyright:
© 2020 Elsevier Inc.


  • Cancer
  • Cardiovascular disorders
  • Cell death
  • Cell programmed necrosis
  • MLKL
  • Necroptosis
  • Neurodegenerative diseases
  • RIPK1
  • RIPK3

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Review


Dive into the research topics of 'A decade of cell death studies: Breathing new life into necroptosis'. Together they form a unique fingerprint.

Cite this